Cancer charity, drugmaker partner on pancreatic cancer research

08/14/2014 | PharmaTimes (U.K.)

Cancer Research UK and Astellas Pharma announced a two-year collaboration to find new drug targets for pancreatic cancer based on the theory of autophagy. Researchers will first study drug targets for blocking the autophagy pathway in pancreatic cancer cells. Cancer Research UK's commercial arm, Cancer Research Technology, will receive milestone payments and royalties from Astellas for the most promising candidates.

View Full Article in:

PharmaTimes (U.K.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Market Access Manager Electrophysiology HEOR (AEP) - 15000003NZ
Menlo Park, CA
Sales Manager, Employer Programs
PartnerRe Health